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Retinoids, natural and synthetic vitamin A metabolites and
analogues, inhibit the proliferation of several types of tumour
cells, such as head and neck squamous cell carcinoma (SCC)
(Jetten et al, 1990; Lotan, 1994; Oridate et al, 1996), oesophageal
cancer (Xu et al, 1999), lung cancer (Zou et al, 1998; Sun et al,
1999a,b), prostate cancer (Sun et al, 1999c), and cervical cancer
(Lotan et al, 1995; Oridate et al, 1997). The effects of retinoids are
mediated by both nuclear retinoid receptors (RARs and RXRs)
and cytoplasmic retinoic acid binding proteins (CRABP1 and
CRABP2) (Pemrick et al, 1994). Retinoids are used as a chemo-
preventive or chemotherapeutic agent for patients with several
solid tumours, and some successful results from the clinical trials
has been reported (Hong et al, 1990; Lippman et al, 1993; Mitchell
et al, 1995). Hong et al (1990) reported that 13-cis retinoic acid
(13-cisRA) suppressed the oral pre-malignant lesions and
decreased the incidence of second primary tumours in head and
neck cancer. Furthermore, all-trans retinoic acid (ATRA) is
currently used as a standard drug for acute premyelocytic
leukaemia, and these successful treatments are recognized as the
first example of differentiation therapy (Lo-coco et al, 1998).
Molecular mechanisms of the differentiation-inducing action of
ATRA on acute premyelocytic leukaemia is well understood (He
et al, 1999). On the solid tumours, however, the mechanisms of the
action of retinoids was not fully understood. 
Oral SCC are characterized by a high degree of local invasion
and a high rate of metastasis to cervical lymph nodes, but a low
rate of metastases to distant organs. Oral SCC frequently show
the local recurrence after initial treatment, probably due to
micro-invasion and/or micro-metastasis of the tumour cells 
at primary site. We recently reported that oral SCC cells
produced a large amount of matrix-degrading enzymes and that
the net activity of MMP2 (active-MMP2/TIMP2) produced by
cancer cells contributed to lymph-node metastasis in a nude
mouse orthotopic inoculation model (Kawamata et al, 1997).
Furthermore, we demonstrated that active-MMP2 in cancer cell
nests played an important role on lymph node metastasis of oral
SCC patients by microdissection-zymography of human oral
SCC tissues (Kawamata et al, 1998). Thus, MMPs may play 
an important role on the invasion and metastasis of oral cancer 
cells. 
In order to use retinoids more effectively on the patients with
several malignancies, including oral SCC, the effect of retinoids
not only on the proliferation of the cells but also on the other
biological characteristics, such as invasiveness or angiogenesis,
should be examined. In this study, we investigated the effect of
retinoids on the invasive potentials of oral SCC cells in vitro. First,
we examined the expression of nuclear receptors and cytoplasmic
binding proteins for retinoids in oral SCC cell lines, BHY and 
HNt which were established and characterized in our laboratory
(Kawamata et al, 1997). Then we examined the effect of low-
dose ATRA (10–8 M) and 13-cisRA (10–8 M), which did not affect
the cell growth, on the expression or activity of the matrix-
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degrading enzymes, and the in vitro invasiveness of the oral SCC
cells. 
MATERIALS AND METHODS 
Cells and cell culture 
BHY and HNt (Kawamata et al, 1997) cells were derived from
human oral SCC tumours from patients. HT1080 cells are a human
fibrosarcoma cell line purchased from Dai-Nippon Seiyaku,
Osaka, Japan. All of the cells were maintained in DMEM (Life
Technologies, Inc, Gaithersburg, MD) supplemented with 10%
FCS (Bio-Whittaker, Walkersville, MD), 100 mg ml–1 strepto-
mycin, and 100 U ml–1 penicillin, 0.25 mg ml–1 Amphotericin B
(Life Technologies, Inc.) in a humidified atmosphere of 95% air
and 5% CO2 at 37˚C. 
MTT assay 
We examined the effect of ATRA (Sigma, St. Louis, MO) and 13-
cisRA (Sigma) on the growth of the cells by an assay in which MTT
(Sigma) was used. Cells were seeded on a 96-well plate (Falcon;
Becton Dickinson Labware, Lincoln Park, NJ) at 5 ´ 103 cells per
well in DMEM containing 10% FCS. After 24 h, cells were washed
twice with DMEM without FCS and cultured in DMEM without
FCS in the presence or absence of ATRA (10–6, 10–7 and 10–8 M) or
13-cisRA (10–6, 10–7 and 10–8 M). After 3 days, the number of cells
was quantitated by MTT assay (Carmichael et al, 1987). 
Gelatinase zymography and reverse gelatinase
zymography 
Cells were grown to confluence in 60 mm dishes (Falcon) in the
serum-supplemented medium, washed twice with serum-free
DMEM, and cultured in 3 ml of serum-free DMEM in the pres-
ence or absence of ATRA (10–8 M) or 13-cisRA (10–8 M) for an
additional 48 h. The medium was collected, clarified by centrifu-
gation at 1800 g, and concentrated down to 0.1 ml approximately
30-fold by Centricon 10 (cut-off, Mr 10 000; Millipore Corp,
Bedford, MA). We have already confirmed that the process of the
protein concentration did not activate the progelatinases in the
samples (Kawamata et al, 1997). The protein concentration of 
the samples are determined by Bio-Rad protein assay (Bio-Rad,
Hercules, CA). The gels for zymorgraphy were composed of
gelatin (0.1%; Sigma) and polyacrylamide (10%), and for reverse
zymography, of gelatin (0.1%), polyacrylamide (12.5%) and
concentrated conditioned medium (100 mg ml–1) of the human
fibrosarcoma cell line (HT1080) as a source of gelatinases. 5 mg
protein samples from BHY and HNt, and 1 mg protein sample
from HT1080, or 10 mg protein samples from all cells for reverse
zymography were added to a loading buffer (50 mM Tris-HCl 
(pH 6.8), 2% SDS, 0.1% bromophenol blue, and 10% glycerol) 
and were not heated before electrophoresis. Gels were run at 
30 mA/gel at 4˚C, incubated overnight at 37˚C in 0.05 M Tris-HCl
buffer (pH 7.5) containing 10 mM CaCl2, stained with Coomassie
blue (0.25%), and destained in methanol:acetic acid:water (50:
10:40). Clear zones indicated the presence of gelatinolytic activity
in zymography, and dark zones indicated the presence of gelati-
nase inhibitors in reverse zymography. 
RT-PCR 
Cells grown in monolayers were harvested at early confluence.
RNA was prepared by lysing of cells in a hypotonic buffer
containing Nonidet P-40 (Sigma), followed by removal of nuclei.
Cytoplasmic RNA was reverse-transcribed by Moloney murine
leukaemia virus reverse transcriptase (Life Technologies, Inc) at
42˚C for 60 min using random primer (5 mM; Life Technologies,
Inc.) in 20 ml of the reaction mixture. Subsequently, 1 ml of the
products was subjected to PCR amplification. PCR was performed
as follows: the final concentration of dNTPs and primers in the
reaction mixture were 200 mM and 1 mM, respectively. Taq DNA
polymerase (Takara Biomedicals, Kusatsu, Japan) was added to
the mixture at a final concentration of 0.05 U ml–1, and the reaction
was carried out in a Takara Thermal Cycler MP (Takara Bio-
medicals) under the following conditions: 94˚C for 3 min and then
94˚C for 1 min, 60˚C for 1.5 min, 72˚C for 2.5 min for 30 cycles,
and extension at 72˚C for 4 min. To determine whether conditions
were adequate for semi-quantitative RT-PCR, we reverse-tran-
scribed 0.05, 0.5, 5 and 10 mg of total RNA and amplified the frag-
ments under the same PCR conditions with different numbers of
cycles (20, 24, 28, 32 and 36 cycles). We used 5 mg of cytoplasmic
RNA as a template for reverse transcription and the indicated
cycles on Table 1 for each genes. The primers used were also listed
in Table 1. 
Chromogenic assay for tPA activity 
Chromogenic assay for tPA activity was performed by Spectrolyse/
fibrin kit (Biopool, Ventura, CA) according to the manufacturer’s
instructions. Conditioned medium of all cells was collected and
prepared as described above. Membrane extracts were prepared
as follows: cells were lysed in 20 mM HEPES-HCl (pH 7.5),
150 mM NaCl, 2 mM CaCl2, 1 mM phenyl-methylsulfonyl fluo-
ride, and 2 mg ml–1 of leupeptin. After centrifugation of the lysates
at 700 g for 20 min at 4˚C, the supernatant was further ultra-
centrifuged at 100 000 g for 1 h at 4˚C. The pellet was resus-
pended in 50 mM Tris-HCl (pH 7.5) containing 0.5% Triton
X-100. The protein concentration of samples were determined by
Table 1 Primers used
Upper-stream Down-stream Length of DNA Cycles
frragment (bp)
RAR-a gtctttgccttcgccaaccag gccctctgagttctccaaca 333 26
RAR-b ggagacttcgaagcaagaatg aacacaaggtcagtcagaggac 452 28
RAR-g tgacccagtatgtagaagccag gttccggtcatttcgcacagc 678 28
RXR-a atcagcaaagacctcagccgc aggctctgggtgaacaacgctg 744 35
CRABP1 ctacatcaagacatccaccaccg ctagggatacaagaggcaccaag 446 33
CRABP2 ggtgaatgtgatgctgaggaag ctacagggacaaagggtagaag 706 33Bio-Rad protein assay (Bio-Rad). 500 ng protein samples from
conditioned medium and plasma membrane were subjected to the
chromogenic assay. 
In vitro invasion assay 
Oral SCC cells, 2 ´ 105 cells in Experiment I or 5 ´ 104 cells in
Experiment II, were seeded on Matrigel-coated polycarbonate
filters of 8 mm pore size in triplicate Transwell invasion chambers
(6.5 mm in diameter) (Falcon). Then, ATRA or 13-cisRA at 10–8
M was added in the upper compartment. After 48 h incubation, the
cells and Matrigel on the upper-surface of the membrane were
wiped out with a cotton swab, and the membrane was removed
from the chamber, and stained with haematoxylin-eosin. Plugged
cells in the pore or the cells attached on the lower-surface of the
membrane were counted in 10 fields at high power view (´ 400) in
Experiment I, or in total area of the membrane in Experiment II by
a third person without any knowledge of the treatments. 
RESULTS 
Effect of ATRA and 13-cisRA on the growth of oral SCC
cells in vitro 
Both ATRA and 13-cisRA inhibited the growth of BHY and HNt
cells in a dose-dependent manner (Figure 1). The cell number of
BHY at day 3 was decreased down to 20% and 30% of the control
level (the cell number at day 0) by ATRA (10–6 M) and 13-cisRA
(10–6 M), respectively. On the other hand, the cell number of HNt
was decreased down to 30% and 60% of the control level by
ATRA (10–6 M) and 13-cisRA (10–6 M), respectively. However,
low-dose ATRA (10–8 M) and 13-cisRA (10–8 M) did not affect the
growth of BHY cells at all, and minimally affected the growth of
HNt cells (Figure 1). Data are representative of 2 separate experi-
ments with similar results. 
Expression of retinoid nuclear receptors and
cytoplasmic retinoic acid binding proteins in oral SCC
cells 
We examined the expressions of mRNA for retinoid nuclear recep-
tors and cytoplasmic retinoic acid binding proteins in oral SCC
cells by semi-quantitative RT-PCR method. BHY cells expressed all
of RARs (RARa, b and g), RXRa, (Figure 2A) and CRABP1 and
CRABP2 (Figure 2B). On the other hand, HNt cells lacked the ex-
pression of RARb, but expressed RARa, RARg, RXRa, (Figure 2A)
and CRABP1 and CRABP2 (Figure 2B). We sequenced all of the
fragments, and confirmed the fragments were amplified from the
genes of our interest. (data not shown). 
Activation of proMMPs by treatment with low-dose
ATRA and 13-cisRA in oral SCC cells 
We reported that BHY and HNt cells expressed several types of
MMP at very high level (Kawamata et al, 1997). Then, we exam-
ined the effect of low-dose RAs on the expression and the activa-
tion of MMPs. When we treated BHY and HNt cells by ATRA
(10–8 M) or 13-cisRA (10–8 M) for 48 h, the gelatinolytic band of
proMMP9 moved slightly faster than that in the untreated controls,
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Figure 1 Effect of RAs on in vitro growth of oral SCC cells. The columns
show the average of 8 samples and the bars show SD. Data are
representative of 2 separate experiments with similar results. *, P < 0.01; 
**, not significant when compared to that of control by one-way ANOVA 
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and the movement of the bands in the treated cells corresponded to
that in HT1080 cells (Figure 3A, B). Then, the shifted bands were
considered as the proteolytically activated form of MMP9.
Furthermore, the intensity of proMMP2 bands in BHY and HNt
cells was decreased, and the proteolytically activated form of
MMP2 apparently appeared by treatment with ATRA (10–8 M) or
13-cisRA (10–8 M) (Figure 3A, B). The activation of proMMPs by
RAs in BHY and HNt cells was inhibited by treatment with a
serine proteinase inhibitor, aprotinin (Figure 3A, B). Data are
representative of 3 separate experiments with similar results. 
Effect of RAs on the activity of tPA and uPA in oral SCC
cells 
We examined the effect of low-dose RAs (10–8 M) on tPA activity
in the oral SCC cells. ATRA significantly (P < 0.05; one-way
ANOVA) increased the activity of tPA in the medium as well as on
the plasma membrane of BHY and HNt cells (Figure 4A, B). 13-
cisRA also significantly (P < 0.05; one-way ANOVA) increased
the activity of tPA in the medium of BHY cells and on the plasma
membrane of HNt cells (Figure 4A, B). 13-cisRA slightly
increased the activity of tPA on the plasma membrane of BHY and
in the medium of HNt, although the effect of 13-cisRA on these
cells did not reach the significant level (Figure 4A, B). Data are
representative of 2 separate experiments with similar results. We
also examined the effect of RAs on the activity of uPA in the
medium of the oral SCC cells by uPA zymography. However, low-
dose RAs did not affect the activity of uPA from oral SCC cells
(data not shown). 
Effect of RAs on the expression of MT1-MMP and the
activity of TIMPs in oral SCC cells 
We previously reported that BHY and HNt cells expressed MT1-
MMP and TIMPs (TIMP1 and TIMP2) (Kawamata et al, 1997).
Then, we examined the effect of low-dose RAs (10–8 M) on the
expression of MT1-MMP and the activity of TIMPs in the oral
SCC cells. The expression of MT1-MMP was examined by semi-
quantitative RT-PCR, and the activity of TIMPs was examined
by reverse-zymography. The expression of MT1-MMP and the
activity of TIMPs (TIMP1 and TIMP2) were not affected by low-
dose RAs (data not shown). 
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Effect of RAs on the invasion of oral SCC cells 
We examined the effect of low-dose RAs (10–8 M) on in vitro inva-
siveness of the oral SCC cells. We repeated the Experiment I
twice, and Experiment II 4 times, and obtained similar results from
these separate experiments. Here, we presented the representative
results from the Experiment I and Experiment II. In Experiment I,
13-cisRA significantly enhanced the in vitro invasiveness of BHY
cells (P = 0.03; one-way ANOVA) (Figure 5A). ATRA also en-
hanced the invasiveness of BHY cells, but the effect of ATRA 
did not reach the significant level (P = 0.08; one-way ANOVA)
(Figure 5A). Both ATRA and 13-cisRA did not affect the invasive-
ness of HNt cells (Figure 5A). In Experiment II, we further exam-
ined the effect of ATRA on the invasiveness of BHY cells. In this
experimental condition, ATRA significantly enhanced the inva-
siveness of BHY cells (P = 0.016; one-way ANOVA) (Figure 5B).
A serine proteinase inhibitor, aprotinin slightly inhibited the effect
of ATRA, although the effect did not reach the significant level 
(P = 0.16; one-way ANOVA) (Figure 5B). If we increased the
concentration of aprotinin, aprotinin affects the viability of the
cells. Then, we could not demonstrate the apparent inhibitory
effect of aprotinin on the action of RAs. 
DISCUSSION 
In this investigation, we examined the effect of retinoic acids on
the growth and the invasive potentials of the oral SCC cells in
vitro. We demonstrated that ATRA (10–6 and 10–7 M) and 13-cisRA
(10–6 and 10–7 M) inhibited the growth of the oral SCC cells (BHY
and HNt) in vitro, but low-dose ATRA (10–8 M) and 13-cisRA
(10–8 M) marginally affect the growth of the cells. Low-dose RAs
(10–8 M) enhanced the activity of tPA, and converted proMMP2
and proMMP9 to active forms. Furthermore, low-dose RAs
enhanced the in vitro invasiveness of BHY cells. 
Several investigators reported that retinoids inhibited the inva-
sion of tumour cells. Hendrix et al (1990) and Wood et al (1990)
noted that retinoic acid inhibited the invasiveness of melanoma
cells by the down-regulation of gelatinases, tPA, and a motility
factor receptor, and up-regulation of laminin receptor. Yamamoto
et al (1995) reported that retinoic acid inhibited the expression of
MMP7 in colon cancer cells. Webber and Waghray (1995) also
demonstrated that retinoic acid inhibited the invasion of prostate
cancer by the inhibition of uPA activity. Furthermore, Vermenler et
al (1995) reported that retinoids stimulated the cell to cell adhesion
of cancer cells, and inhibited the invasion of these cancer cells in
vitro. However, retinoids were used at the concentrations which
might affect the cell growth as well as the invasion in the most of
the experiments reported. In this study, we used the RAs at very
low concentration (10–8 M), which did not affect the cell growth, to
see the effect of RAs on the invasiveness of the cells. Before we
started the experiment, we expected that low-dose RAs may
inhibit the expression and activity of MMPs and in vitro invasive-
ness of the cells. However, contrary to our expectation, low-dose
RAs apparently enhanced the in vitro invasiveness of the cells.
These observations were not limited to our oral SCC cells. Tiberio
et al (1997) recently reported that ATRA enhanced the invasion of
neuroblastoma cells by the induction of tPA. 
It is well known that RAs at the physiological concentration
enhance the activity of uPA and tPA (Bulen et al, 1997; Lansink et
al, 1998). RA-activated retinoic acid receptors directly bind to the
retinoic acid responsive element on the tPA gene promoter, and
induce the transcriptional activation of tPA gene (Bulen et al,
1997). Plasminogen activators (uPA and tPA), and plasmin, which
was proteolytically produced by the plasminogen activators, can
activate the latent TGF-b and its family members (Imai et al,
1997), HGF (Mars et al, 1993), and proMMPs (Baramova et al,
1997). Thus, RAs enhance the migration, invasion and differentia-
tion of the cells, and may act as a morphogen during the embryo-
genesis and the development. Therefore, our observations were not
conflicting with the previous reports concerning the function of
RAs. 
Lotan and his colleagues reported that several cancer cells
lacked the expression of RARb, and the responsiveness of the
cancer cells to retinoids were highly dependent on the expression
of RARb (Lotan, 1997; Wan et al, 1999). Then they concluded that
RARb may be a candidate of the tumour suppressor gene (Lotan,
1997). In our oral SCC cells, BHY cells expressed all of RARs
(RARa, b, and g), RXRa, and CRABPs (CRABP1 and CRABP2).
HNt cells, however, lacked the expression of RARb, but expressed
other nuclear receptors and CRABPs. BHY cells were derived
from highly differentiated SCC, and HNt cells were derived from
poorly differentiated SCC (Kawamata et al, 1997). BHY cells
formed highly differentiated squamous cell carcinoma, but did not
metastasize to any distant organs in nude mice (Kawamata et al,
Figure 5 In vitro invasion assay. Panel A, experiment I; panel B, experiment
II. The columns show the average of 3 samples and the bars show SD. 
Data are representative of 2 separate experiments with similar results. 
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1997). HNt tumours in nude mice were poorly differentiated squa-
mous cell carcinoma, and frequently metastasized to cervical
lymph nodes (Kawamata et al, 1997). Thus, the lack of RARb may
partially account for the aggressive behaviour of HNt cells in nude
mice. Furthermore, the different expression pattern of the RA
receptors may contribute the different responsiveness of BHY and
HNt cells to RAs on the in vitro invasion assay. Low-dose RAs
apparently enhanced the invasiveness of BHY cells, but the effect
of low-dose RAs on the invasiveness of HNt cells was not demon-
strable in this experimental condition, although low-dose RAs
enhanced the activity of tPA and activation of proMMPs in both
cells. The other factors, such as TGF-b and HGF may affect the in
vitro invasiveness of the cells. Bracke et al (1992) reported that
ATRA affected the invasiveness of human mammary carcinoma
variants (MCF-7/6 and MCF-7/AZ) from the same parental cells
(MCF-7) in opposite directions. They showed that treatment with
ATRA (10–6 M) inhibited the invasion and ruffling of MCF7/6
cells, while the same treatment enhanced the invasion and ruffling
of MCF-7/AZ cells. Their published findings may support our
present observations. 
Retinoids are now used as a chemopreventive or chemothera-
peutic agent for patients with several solid tumours (Hong et al,
1990; Lippman et al, 1993; Mitchell et al, 1995). Furthermore, a
triple combination of 5-fluorouracil, vitamin A and cobalt-60 radi-
ation, so-called FAR therapy, has been applied to treat the patients
with head and neck tumours (Komiyama et al, 1978). If the intra-
tumoral concentration of RAs does not reach the antiproliferative
dose, RAs might enhance the invasion and migration of the cancer
cells. Then RAs should be used at enough high concentration to
show the anti-proliferative effect or differentiation-inducing effect
on the cancer cells. 
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